ANTARES PHARMA, INC.

ATRSUnited States

28 filed reports · 336 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$184M

FY2021 · to Dec 31, 2021

up +23.0% vs $150M

10-K

Net income

$46.3M

FY2021 · to Dec 31, 2021

down −17.6% vs $56.2M

10-K

Operating income

$65.9M

FY2021 · to Dec 31, 2021

up +384% vs $13.6M

10-K

Latest quarter

Revenue

$41.6M

Q1 FY2022 · to Mar 31, 2022

down −1.2% vs $42.1M

10-Q

Net income

-$2.32M

Q1 FY2022 · to Mar 31, 2022

a year earlier: $3.79M

10-Q

Operating income

-$2.82M

Q1 FY2022 · to Mar 31, 2022

a year earlier: $5.39M

10-Q

Filed reports

28 reports · Jun 2015 to Mar 2022

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR212,505Jun 2015 to Mar 2022
Annual · 10-KSEC EDGAR72,912Dec 2015 to Dec 2021

Documents

PeriodTypePeriod endPublishedFactsSource
FY2022 Q110-Q2022-03-312022-05-10295Open
FY202110-K2021-12-312022-03-03813Open
FY2021 Q310-Q2021-09-302021-11-04178Open
FY2021 Q210-Q2021-06-302021-08-05163Open
FY2021 Q110-Q2021-03-312021-05-06109Open
FY202010-K2020-12-312021-03-02380Open
FY2020 Q310-Q2020-09-302020-11-05110Open
FY2020 Q210-Q2020-06-302020-08-0699Open
FY2020 Q110-Q2020-03-312020-05-05102Open
FY201910-K2019-12-312020-03-03379Open
FY2019 Q310-Q2019-09-302019-11-05115Open
FY2019 Q210-Q2019-06-302019-08-06115Open

Financial data

336 concepts · 5,417 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial322 concepts · 5,049 facts · Dec 2013 to Mar 2022

  • Comprehensive income net of tax42 · Dec 2013 to Mar 2022
  • Net income loss42 · Dec 2013 to Mar 2022
  • Operating income loss42 · Dec 2013 to Mar 2022
  • Other comprehensive income foreign currency transaction and translation adjustment net of tax portion attributable to parent42 · Dec 2013 to Mar 2022
  • Other nonoperating income expense42 · Dec 2013 to Mar 2022
  • Research and development expense42 · Dec 2013 to Mar 2022
  • Revenue42 · Dec 2013 to Mar 2022
  • Selling general and administrative expense42 · Dec 2013 to Mar 2022
  • Capital expenditures incurred but not yet paid40 · Dec 2013 to Mar 2022
  • Depreciation depletion and amortization40 · Dec 2013 to Mar 2022
  • Increase decrease in accounts payable40 · Dec 2013 to Mar 2022
  • Increase decrease in accounts receivable40 · Dec 2013 to Mar 2022
  • Increase decrease in accrued liabilities and other operating liabilities40 · Dec 2013 to Mar 2022
  • Increase decrease in inventories40 · Dec 2013 to Mar 2022
  • Increase decrease in prepaid deferred expense and other assets40 · Dec 2013 to Mar 2022
  • Payments to acquire property plant and equipment40 · Dec 2013 to Mar 2022
  • Share based compensation40 · Dec 2013 to Mar 2022
  • Share based compensation arrangement by share based payment award options outstanding number39 · Dec 2013 to Mar 2022
  • Share based compensation arrangement by share based payment award options outstanding weighted average exercise price39 · Dec 2013 to Mar 2022
  • Stockholders equity (US GAAP)39 · Dec 2013 to Mar 2022
  • Cash and cash equivalents at carrying value38 · Dec 2013 to Mar 2022
  • Payments related to tax withholding for share based compensation38 · Dec 2013 to Mar 2022
  • Shares paid for tax withholding for share based compensation38 · Dec 2013 to Mar 2022
  • Accounts payable current37 · Dec 2014 to Mar 2022

Product10 concepts · 223 facts · Mar 2014 to Mar 2022

  • Revenue94 · Dec 2014 to Mar 2022
  • Cost of goods and services sold (US GAAP)55 · Dec 2016 to Mar 2022
  • Revenue From Contract With Customer Accruals And Adjustments20 · Dec 2018 to Dec 2021
  • Revenue From Contract With Customer Payments And Other Reserve Reductions20 · Dec 2018 to Dec 2021
  • Contract with customer liability revenue recognized15 · Mar 2017 to Mar 2022
  • Product Revenue10 · Mar 2014 to Dec 2015
  • Deferred Costs Cost Recognized3 · Mar 2017 to Jun 2017
  • Revenue Recognition Changes In Net Income Loss3 · Mar 2017 to Dec 2017
  • Deferred revenue revenue recognized12 · Mar 2017 to Jun 2017
  • Revenue Recognition Changes In Earnings Per Share1 · Mar 2017

Geography4 concepts · 145 facts · Dec 2013 to Mar 2022

  • Revenue138 · Dec 2013 to Mar 2022
  • Income loss from continuing operations3 · Dec 2014 to Dec 2016
  • Amount Of Net Operating Loss Carryforwards Used To Offset Taxable Income2 · Dec 2014 to Dec 2015
  • Income tax expense benefit2 · Dec 2014 to Dec 2015

Segments

368 facts

Figures broken down by business line, region, product or another axis the company reports on.

Product or servicesrt:ProductOrServiceAxis10 members · 193 facts

  • Product sales [Member]54 · Dec 2016 to Mar 2022
  • Licensing And Development Revenue [Member]44 · Dec 2016 to Mar 2022
  • Royalties [Member]27 · Dec 2016 to Mar 2022
  • Cost of development revenue [Member]25 · Dec 2016 to Mar 2022
  • Patient Discount Programs [Member]8 · Dec 2018 to Dec 2021
  • Prompt Payment Discounts [Member]8 · Dec 2018 to Dec 2021
  • Rebates and Chargebacks [Member]8 · Dec 2018 to Dec 2021
  • Returns [Member]8 · Dec 2018 to Dec 2021
  • Wholesaler Distribution Fees [Member]8 · Dec 2018 to Dec 2021
  • OTREXUP [Member]3 · Mar 2017 to Dec 2017

Statement geographicalus-gaap:StatementGeographicalAxis4 members · 73 facts

  • Europe [Member]22 · Dec 2013 to Mar 2018
  • Other [Member]22 · Dec 2013 to Mar 2018
  • U.S [Member]22 · Dec 2013 to Mar 2018
  • Switzerland [Member]7 · Dec 2014 to Dec 2016

Statement geographicalsrt:StatementGeographicalAxis3 members · 72 facts

  • Europe [Member]27 · Dec 2016 to Mar 2022
  • U.S [Member]27 · Dec 2016 to Mar 2022
  • Other [Member]18 · Dec 2016 to Dec 2021

Product or serviceus-gaap:ProductOrServiceAxis1 member · 30 facts

  • OTREXUP [Member]30 · Mar 2014 to Dec 2017

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of ANTARES PHARMA, INC. (ATRS) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.